由于效率低下,Sanofi和Johnson和Johnson停止了E. Coli疫苗研究,费用为Sanofi 250M美元。 Sanofi and Johnson & Johnson halt E. coli vaccine study due to ineffectiveness, costing Sanofi $250M.

Sanofi和Johnson & Johnson停止了第三阶段针对肠外致病性E.大肠杆菌的疫苗研究,因为效果不足。 Sanofi and Johnson & Johnson have stopped a phase 3 study for a vaccine targeting extraintestinal pathogenic E. coli due to insufficient efficacy. 与60岁及60岁以上有尿道感染史的成年人的安慰剂相比,该疫苗未能有效预防侵入性大肠杆菌病。 The vaccine failed to prevent invasive E. coli disease effectively compared to a placebo in adults aged 60 and older with a history of urinary tract infections. Sanofi记录了2.5亿美元的减值费,对全年的EPS造成15美分的影响。 Sanofi has recorded a $250 million impairment charge, impacting its full-year EPS by 15 cents.